Insomnia & Anxiety Drugs: Know the Risks
- Paris - the National Agency for the Safety of Medicines and Health Products (ANSM) is raising concerns about the widespread use and potential dangers of benzodiazepines in
- Benzodiazepines, commonly prescribed for anxiety and insomnia, are intended for short-term use.
- “These drugs are widely used in France,” said Professor Catherine Paugam-Burtz, director general of the ANSM.
French Agency Warns of Benzodiazepine Risks, Launches Awareness Campaign
Table of Contents
Paris – the National Agency for the Safety of Medicines and Health Products (ANSM) is raising concerns about the widespread use and potential dangers of benzodiazepines in France, where more than 9 million people use the medication. The agency has launched a public awareness campaign to promote safer usage.
Over-prescription and Prolonged Use
Benzodiazepines, commonly prescribed for anxiety and insomnia, are intended for short-term use. However, a meaningful portion of French patients are treated for longer than recommended. According to the ANSM, about 40%, or 3.6 million people,are on benzodiazepines beyond the recommended duration.
“These drugs are widely used in France,” said Professor Catherine Paugam-Burtz, director general of the ANSM. She noted a recent survey indicated that 1 in 4 French people have taken a benzodiazepine. She added that less than 60% of patients are aware of the recommended short-term usage, which is less than three months for anxiety and less than three weeks for insomnia.
Dr. Philippe Vella, medical director of the ANSM, stated that France is the second-highest consumer of benzodiazepines in Europe, with approximately 34 units per inhabitant per year, trailing only Spain’s 54 units.The United Kingdom and germany consume significantly less, at around 5 and 7 units, respectively.
Risks and Side Effects
Benzodiazepines act on the central nervous system and, while effective, pose risks including dependence, falls (particularly dangerous for the elderly), and memory problems. They can also impair the ability to operate machinery and drive vehicles. Mehdi benkebil, director of surveillance at the ANSM, noted that benzodiazepines are implicated in a large number of drug-related road accidents.
The ANSM strongly advises against combining benzodiazepines with alcohol, as it can amplify side effects. “The longer the duration of treatment,the more these risks are increased,” Dr. Vella said, emphasizing that the drugs treat symptoms, not underlying causes.
Targeting Young Adults and Seniors
The awareness campaign specifically targets 18-to-25-year-olds and seniors. Dr. Vella explained that those over 65 account for about half of benzodiazepine prescriptions and represent a majority of patients with prescriptions exceeding recommended durations.The agency has also observed increased consumption among young women in recent years.
Promoting Non-Drug Alternatives
The ANSM campaign promotes non-drug alternatives for managing anxiety and insomnia. Slogans such as “insomnia drugs, it is for a few nights. Meditation is without moderation” and “anxiety drugs, it is indeed for a short duration.See its friends, it is indeed non-stop” encourage alternative approaches.
For sleep disorders,the agency recommends reducing stimulants like coffee,alcohol,and tobacco,avoiding large evening meals,establishing consistent sleep routines,limiting naps,and reducing exposure to noise,light,and screens before bed. For anxiety, the ANSM suggests physical and relaxing activities like yoga, gardening, or reading, and seeking the root causes of anxiety with the help of a psychologist or psychiatrist.
Guidance for Patients and Doctors
Elodie Massé, ANSM communications director, emphasized that the campaign aims to encourage dialog with doctors. She suggested patients discuss medication options with their doctors. The ANSM has developed a brochure with the College of General Medicine to aid practitioners in these discussions.
The ANSM advises against abruptly stopping long-term benzodiazepine use, as it can cause withdrawal symptoms like confusion and hallucinations. Rather, the agency recommends a gradual reduction in dosage under a doctor’s supervision. Melatonin is cited as a possible alternative treatment for some individuals.
Smaller Packaging to Curb Overuse
The ANSM is working with pharmaceutical companies to make smaller packages of hypnotic benzodiazepines (5-7 tablets) available. Dr. Vella explained that this initiative aims to address short-term treatment needs and prevent patients from stockpiling medication, which can lead to prolonged use or sharing with others. these smaller packages are gradually entering the market.
The ANSM urges doctors and pharmacists to embrace this prospect to promote responsible benzodiazepine use.
Benzodiazepines in France: A Q&A on Risks,Usage,and the ANSM Campaign
Introduction
This article analyzes the recent warnings from the National Agency for the Safety of Medicines and Health Products (ANSM) in France regarding benzodiazepine use and the launch of their public awareness campaign. We will explore the nuances of benzodiazepine usage, its associated risks, and the alternatives proposed by the ANSM. Let’s dive in!
Q: What are benzodiazepines, and why is the ANSM concerned about their use in France?
A: Benzodiazepines are a class of psychoactive drugs primarily prescribed too treat anxiety and insomnia. They work by affecting the central nervous system. The ANSM is concerned as, as the article states, more than 9 million people in France use these medications, making them a very common part of the health landscape.The agency’s concern stems from the potential for overuse, dependency, and associated health problems. Studies show that 1 in 4 French people have,at some time,taken a benzodiazepine.
Q: How prevalent is benzodiazepine use in France compared to other countries?
A: the article mentions that France is the second-highest consumer of benzodiazepines in Europe, wiht approximately 34 units consumed per inhabitant per year. Only Spain has a higher rate, at 54 units per person per year.In comparison, the United Kingdom and Germany consume considerably less, around 5 and 7 units respectively. This high consumption rate highlights the need for greater awareness and safer usage practices.
Q: What are the recommended guidelines for benzodiazepine use?
A: Benzodiazepines are primarily intended for short-term use.The ANSM recommends that benzodiazepines are used for the shortest duration possible. The recommended duration is less than three months for anxiety and less than three weeks for insomnia. Less than 60% of patients are aware of the recommended short-term usage. Prolonged use increases the risk of side effects.
Q: What are the primary risks and side effects associated with benzodiazepines?
A: Benzodiazepines can lead to dependence,especially with prolonged use. Other risks include:
Falls, which is especially dangerous for the elderly.
Memory problems.
Impaired ability to operate machinery or drive.
Benzodiazepines are implicated in a large number of drug-related road accidents, according to Mehdi Benkebil, director of surveillance at the ANSM.
Combining benzodiazepines with alcohol amplifies the side effects.
Q: Who is the ANSM targeting with its awareness campaign?
A: The ANSM is specifically targeting two key demographics:
18-to-25-year-olds: Consumption has increased among young women in recent years.
Seniors (65+): This group accounts for roughly half of all benzodiazepine prescriptions and makes up a considerable portion of patients exceeding recommended treatment durations.
Q: What non-drug alternatives are promoted by the ANSM?
A: The ANSM advocates for non-drug alternatives to manage anxiety and insomnia. Their campaign promotes this with slogans such as:
“Insomnia drugs, it is indeed for a few nights. Meditation is without moderation.”
“Anxiety drugs, it is indeed for a short duration. See its friends, it is indeed indeed non-stop.”
The ANSM recommends these lifestyle changes to patients:
For sleep disorders: Reduce the intake of stimulants like coffee, alcohol, and tobacco; avoid large evening meals; establish consistent sleep routines; limit naps, and minimize exposure to light, noise, and screens before bed.
For anxiety: Engage in physical and relaxing activities,such as yoga,gardening,or reading. Seek professional help to address the underlying causes of anxiety with a psychologist or psychiatrist.
Q: How does the ANSM guide patients and doctors regarding benzodiazepine use?
A: The ANSM is encouraging open dialog between patients and their doctors about medication options. It developed a brochure with the College of General Medicine to aid practitioners in these discussions. The ANSM also advises against suddenly stopping benzodiazepines, as it can cause withdrawal symptoms.
Q: Why is the ANSM working to make smaller packages of benzodiazepines available?
A: The ANSM is working with pharmaceutical companies to introduce smaller packages (5-7 tablets) of hypnotic benzodiazepines. This initiative aims to:
Address short-term treatment needs.
Prevent patients from stockpiling medication, which can lead to prolonged use or sharing with others.
Q: Could you summarize key points about responsible benzodiazepine use?
A: The ANSM promotes responsible benzodiazepine use by encouraging dialogue between patients and their doctors. It recommends individuals discuss treatment options for anxiety and insomnia with their healthcare professionals. Other recommendations include:
Discuss medication options with a doctor.
Avoid abruptly stopping benzodiazepines to prevent withdrawal.
Gradually reduce dosage under medical supervision.
Explore option treatments like melatonin.
Be aware of the risks, including dependence and side effects.
Understand the medication’s short-term application.
Q: What kind of Benzodiazepines are mentioned in the “Note” of the article?
A: The article provides these examples:
For anxiety:
Lexomil
Temesta
For insomnia:
Stilnox
mogadon
* Imovan
| Aspect | Details |
| ——————— | ————————————————————————————————————————————————————————————————— |
| Issue | Overuse and risks associated with benzodiazepines in France. |
| Context | The ANSM is raising concerns and launching a public awareness campaign. |
| Prevalence | france is the second-highest consumer of benzodiazepines in Europe.|
| Risks | Dependence, falls, memory problems, impaired motor skills, and road accidents. |
| Target Audience | young adults (18-25) and seniors (65+). |
| Alternatives | Non-drug approaches include sleep hygiene practices, physical activities, and professional help to address the root causes of anxiety and insomnia. |
| ANSM’s Actions | Promoting non-drug alternatives, encouraging dialogues between patients and doctors, and providing smaller medication packages. |
| Key Recommendations | Short-term use as advised by a doctor, gradual dosage reduction if discontinuing the medication, and a need for open discussion about treatment plans with healthcare providers. |
Worth a look
- Quitting After Cancer Diagnosis: Misconception vs. Survival Reality
- UK Nursing Union Cuts Ties With Israeli Drugmaker Teva Over Military Links and Misconduct
- Cockpit Lockout Risks Expose Gaps in Global Airline Safety Rules (archyde.com)
- Apple to Limit Mac Disk Access Due to AI Security Risks (time.news)